JP2017509624A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017509624A5 JP2017509624A5 JP2016556709A JP2016556709A JP2017509624A5 JP 2017509624 A5 JP2017509624 A5 JP 2017509624A5 JP 2016556709 A JP2016556709 A JP 2016556709A JP 2016556709 A JP2016556709 A JP 2016556709A JP 2017509624 A5 JP2017509624 A5 JP 2017509624A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- antibody
- patient
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461954094P | 2014-03-17 | 2014-03-17 | |
| US61/954,094 | 2014-03-17 | ||
| US201462025400P | 2014-07-16 | 2014-07-16 | |
| US62/025,400 | 2014-07-16 | ||
| US201462043182P | 2014-08-28 | 2014-08-28 | |
| US62/043,182 | 2014-08-28 | ||
| EP15305293 | 2015-02-26 | ||
| EP15305293.1 | 2015-02-26 | ||
| PCT/US2015/020564 WO2015142668A1 (en) | 2014-03-17 | 2015-03-13 | Methods for reducing cardiovascular risk |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020097344A Division JP2020143156A (ja) | 2014-03-17 | 2020-06-04 | 心血管リスクを低減させる方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017509624A JP2017509624A (ja) | 2017-04-06 |
| JP2017509624A5 true JP2017509624A5 (enExample) | 2018-04-12 |
Family
ID=52648962
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016556709A Pending JP2017509624A (ja) | 2014-03-17 | 2015-03-13 | 心血管リスクを低減させる方法 |
| JP2022116854A Pending JP2022141868A (ja) | 2014-03-17 | 2022-07-22 | 心血管リスクを低減させる方法 |
| JP2024115429A Pending JP2024147744A (ja) | 2014-03-17 | 2024-07-19 | 心血管リスクを低減させる方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022116854A Pending JP2022141868A (ja) | 2014-03-17 | 2022-07-22 | 心血管リスクを低減させる方法 |
| JP2024115429A Pending JP2024147744A (ja) | 2014-03-17 | 2024-07-19 | 心血管リスクを低減させる方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20150284473A1 (enExample) |
| EP (2) | EP4403213A3 (enExample) |
| JP (3) | JP2017509624A (enExample) |
| KR (3) | KR20220157516A (enExample) |
| CN (3) | CN114642661A (enExample) |
| AU (3) | AU2015231713B2 (enExample) |
| CA (1) | CA2942549A1 (enExample) |
| EA (1) | EA039310B1 (enExample) |
| ES (1) | ES2978990T3 (enExample) |
| HU (1) | HUE066839T2 (enExample) |
| IL (1) | IL304491A (enExample) |
| MX (1) | MX380767B (enExample) |
| PL (1) | PL3119810T3 (enExample) |
| WO (1) | WO2015142668A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| WO2010147994A1 (en) | 2009-06-15 | 2010-12-23 | Amarin Pharma, Inc. | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| BR112013018740A2 (pt) | 2011-01-28 | 2019-01-08 | Sanofi Sa | anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| CN103930444B (zh) | 2011-09-16 | 2020-08-04 | 瑞泽恩制药公司 | 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法 |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| TW202021614A (zh) | 2013-06-07 | 2020-06-16 | 法商賽諾菲生物技術公司 | 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法 |
| US10428157B2 (en) | 2013-11-12 | 2019-10-01 | Sanofi Biotechnology | Dosing regimens for use with PCSK9 inhibitors |
| MX2017000527A (es) * | 2014-07-14 | 2017-08-10 | Amgen Inc | Formulaciones de anticuerpos cristalinos. |
| KR20230074283A (ko) | 2014-07-16 | 2023-05-26 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
| EP3169362B1 (en) * | 2014-07-16 | 2020-06-10 | Sanofi Biotechnology | Methods for treating high cardiovascular risk patients with hypercholesterolemia |
| WO2016046684A1 (en) | 2014-09-23 | 2016-03-31 | Pfizer Inc. | Treatment with anti-pcsk9 antibodies |
| JP2018523684A (ja) | 2015-08-18 | 2018-08-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体 |
| JOP20190112A1 (ar) * | 2016-11-14 | 2019-05-14 | Amgen Inc | علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي |
| US10329620B2 (en) | 2017-01-12 | 2019-06-25 | Cardioforecast Ltd. | Methods and kits for treating cardiovascular disease |
| KR102401796B1 (ko) | 2017-04-13 | 2022-05-25 | 카딜라 핼쓰캐어 리미티드 | 신규의 펩타이드 기재 pcsk9 백신 |
| AU2019231703A1 (en) * | 2018-03-06 | 2020-10-22 | Regeneron Pharmaceuticals, Inc. | Use of PCSK9 inhibitor for reducing cardiovascular risk |
| EP3817768A4 (en) * | 2018-07-02 | 2022-07-06 | Abcentra, LLC | Compositions and methods for reduction of lipoprotein a formation and treatment of aortic valve sclerosis and aortic stenosis |
| CN112912071A (zh) * | 2018-08-17 | 2021-06-04 | 阿玛林制药爱尔兰有限公司 | 降低接受他汀类药物治疗的受试者对外周动脉血运重建的需求的方法 |
| ES2983568T3 (es) | 2018-09-24 | 2024-10-23 | Amarin Pharmaceuticals Ie Ltd | Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto |
| RS66416B1 (sr) | 2019-01-18 | 2025-02-28 | Astrazeneca Ab | 6'-[[(1s,3s)-3-[[5-(difluorometoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i metode njegove primene |
| AU2020378424A1 (en) * | 2019-11-07 | 2022-06-23 | Medimmune, Llc | Endothelial lipase antibodies for the treatment of cardiovascular diseases |
| EP4058141A4 (en) | 2019-11-12 | 2023-11-22 | Amarin Pharmaceuticals Ireland Limited | METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT WITH Atrial fibrillation and/or atrial flutter |
| BR112022009587A2 (pt) * | 2019-11-18 | 2022-08-02 | Ad Pharmaceuticals Co Ltd | Anticorpo anti-pcsk9 e uso do mesmo |
| EP4135841A1 (en) * | 2020-04-15 | 2023-02-22 | Voyager Therapeutics, Inc. | Tau binding compounds |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| CN114848849B (zh) * | 2022-04-25 | 2023-11-17 | 南方科技大学 | Pcsk9蛋白抑制剂在治疗心血管疾病中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| BR112013018740A2 (pt) * | 2011-01-28 | 2019-01-08 | Sanofi Sa | anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
-
2015
- 2015-03-13 CN CN202210141115.7A patent/CN114642661A/zh active Pending
- 2015-03-13 AU AU2015231713A patent/AU2015231713B2/en active Active
- 2015-03-13 CN CN202210141133.5A patent/CN114558129A/zh active Pending
- 2015-03-13 CA CA2942549A patent/CA2942549A1/en active Pending
- 2015-03-13 MX MX2016011975A patent/MX380767B/es unknown
- 2015-03-13 EP EP24160083.2A patent/EP4403213A3/en active Pending
- 2015-03-13 JP JP2016556709A patent/JP2017509624A/ja active Pending
- 2015-03-13 US US14/657,192 patent/US20150284473A1/en not_active Abandoned
- 2015-03-13 WO PCT/US2015/020564 patent/WO2015142668A1/en not_active Ceased
- 2015-03-13 KR KR1020227039740A patent/KR20220157516A/ko not_active Ceased
- 2015-03-13 EP EP15712241.7A patent/EP3119810B1/en active Active
- 2015-03-13 HU HUE15712241A patent/HUE066839T2/hu unknown
- 2015-03-13 EA EA201691847A patent/EA039310B1/ru unknown
- 2015-03-13 KR KR1020167028383A patent/KR20160132459A/ko not_active Ceased
- 2015-03-13 KR KR1020247040556A patent/KR20250006995A/ko active Pending
- 2015-03-13 PL PL15712241.7T patent/PL3119810T3/pl unknown
- 2015-03-13 ES ES15712241T patent/ES2978990T3/es active Active
- 2015-03-13 CN CN201580024259.2A patent/CN106794244A/zh active Pending
-
2021
- 2021-02-19 AU AU2021201118A patent/AU2021201118A1/en not_active Abandoned
- 2021-10-19 US US17/504,921 patent/US20220144969A1/en not_active Abandoned
-
2022
- 2022-07-22 JP JP2022116854A patent/JP2022141868A/ja active Pending
-
2023
- 2023-07-16 IL IL304491A patent/IL304491A/en unknown
-
2024
- 2024-07-19 JP JP2024115429A patent/JP2024147744A/ja active Pending
- 2024-07-31 AU AU2024205254A patent/AU2024205254A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017509624A5 (enExample) | ||
| Yu et al. | Expert consensus on the use of human serum albumin in critically ill patients | |
| JP2017506626A5 (enExample) | ||
| Soran et al. | Hypercholesterolaemia–practical information for non-specialists | |
| Rienstra et al. | Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial | |
| Teramoto et al. | Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with Statins–ODYSSEY JAPAN randomized controlled Trial– | |
| Farnier et al. | Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY Phase 3 clinical program trials | |
| JP2017160208A5 (enExample) | ||
| JP2025011161A5 (enExample) | ||
| JP2017503820A5 (enExample) | ||
| JP2017528427A5 (enExample) | ||
| JP2020002171A5 (enExample) | ||
| Mercer et al. | Diabetes mellitus and the heart | |
| JP2017522316A5 (enExample) | ||
| Ito | Dyslipidemia: management using optimal lipid-lowering therapy | |
| JP2012528796A5 (enExample) | ||
| JP2014516953A5 (enExample) | ||
| FI2981255T3 (fi) | Empagliflotsiinin terapeuttiset käytöt | |
| JP2015164964A5 (enExample) | ||
| JP2019507781A5 (enExample) | ||
| JP2016538277A5 (enExample) | ||
| JPWO2019173530A5 (enExample) | ||
| CN107922507A (zh) | 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者 | |
| JP7193455B2 (ja) | 心血管状態におけるインスリンデグルデク | |
| JP2017535551A5 (enExample) |